Browse ADAMTS7

Summary
SymbolADAMTS7
NameADAM metallopeptidase with thrombospondin type 1 motif, 7
Aliases ADAM-TS7; DKFZp434H204; COMPase; a disintegrin and metalloprotease with thrombospondin motifs-7 preproprotei ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix Note=Also found associated with the external cell surface.
Domain PF05986 ADAM-TS Spacer 1
PF01562 Reprolysin family propeptide
PF01421 Reprolysin (M12B) family zinc metalloprotease
PF00090 Thrombospondin type 1 domain
Function

Metalloprotease that may play a role in the degradation of COMP.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0002062 chondrocyte differentiation
GO:0006486 protein glycosylation
GO:0006493 protein O-linked glycosylation
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0032330 regulation of chondrocyte differentiation
GO:0032331 negative regulation of chondrocyte differentiation
GO:0034612 response to tumor necrosis factor
GO:0036065 fucosylation
GO:0036066 protein O-linked fucosylation
GO:0043413 macromolecule glycosylation
GO:0051216 cartilage development
GO:0061035 regulation of cartilage development
GO:0061037 negative regulation of cartilage development
GO:0061448 connective tissue development
GO:0070085 glycosylation
GO:0070555 response to interleukin-1
GO:0071347 cellular response to interleukin-1
GO:0071356 cellular response to tumor necrosis factor
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
Molecular Function GO:0004175 endopeptidase activity
GO:0004222 metalloendopeptidase activity
GO:0008237 metallopeptidase activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005788 endoplasmic reticulum lumen
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5083635: Defective B3GALTL causes Peters-plus syndrome (PpS)
R-HSA-1643685: Disease
R-HSA-3906995: Diseases associated with O-glycosylation of proteins
R-HSA-3781865: Diseases of glycosylation
R-HSA-392499: Metabolism of proteins
R-HSA-5173214: O-glycosylation of TSR domain-containing proteins
R-HSA-5173105: O-linked glycosylation
R-HSA-597592: Post-translational protein modification
Summary
SymbolADAMTS7
NameADAM metallopeptidase with thrombospondin type 1 motif, 7
Aliases ADAM-TS7; DKFZp434H204; COMPase; a disintegrin and metalloprotease with thrombospondin motifs-7 preproprotei ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ADAMTS7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolADAMTS7
NameADAM metallopeptidase with thrombospondin type 1 motif, 7
Aliases ADAM-TS7; DKFZp434H204; COMPase; a disintegrin and metalloprotease with thrombospondin motifs-7 preproprotei ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ADAMTS7 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolADAMTS7
NameADAM metallopeptidase with thrombospondin type 1 motif, 7
Aliases ADAM-TS7; DKFZp434H204; COMPase; a disintegrin and metalloprotease with thrombospondin motifs-7 preproprotei ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ADAMTS7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.0050.0229
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.790.0415
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4410.598
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.7310.036
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7410.726
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.7170.794
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4780.253
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1770.839
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.8330.371
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6010.449
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.5260.126
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2010.156
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ADAMTS7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.35.98.40.576
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414257.117.90.405
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.317.6-3.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8637.516.720.80.58
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)1311018.2-18.20.199
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.611.1-8.50.299
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.523.1-18.60.134
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolADAMTS7
NameADAM metallopeptidase with thrombospondin type 1 motif, 7
Aliases ADAM-TS7; DKFZp434H204; COMPase; a disintegrin and metalloprotease with thrombospondin motifs-7 preproprotei ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ADAMTS7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolADAMTS7
NameADAM metallopeptidase with thrombospondin type 1 motif, 7
Aliases ADAM-TS7; DKFZp434H204; COMPase; a disintegrin and metalloprotease with thrombospondin motifs-7 preproprotei ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ADAMTS7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ADAMTS7.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolADAMTS7
NameADAM metallopeptidase with thrombospondin type 1 motif, 7
Aliases ADAM-TS7; DKFZp434H204; COMPase; a disintegrin and metalloprotease with thrombospondin motifs-7 preproprotei ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ADAMTS7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolADAMTS7
NameADAM metallopeptidase with thrombospondin type 1 motif, 7
Aliases ADAM-TS7; DKFZp434H204; COMPase; a disintegrin and metalloprotease with thrombospondin motifs-7 preproprotei ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ADAMTS7 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolADAMTS7
NameADAM metallopeptidase with thrombospondin type 1 motif, 7
Aliases ADAM-TS7; DKFZp434H204; COMPase; a disintegrin and metalloprotease with thrombospondin motifs-7 preproprotei ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ADAMTS7 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolADAMTS7
NameADAM metallopeptidase with thrombospondin type 1 motif, 7
Aliases ADAM-TS7; DKFZp434H204; COMPase; a disintegrin and metalloprotease with thrombospondin motifs-7 preproprotei ......
Chromosomal Location15q25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ADAMTS7 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.